Alcoholic liver disease. An update.

Association of adiponectin level with biochemical variables and insulin resistance in patients with non-alcoholic fatty liver disease in an Iranian population

Background: Non-alcoholic fatty liver disease is one of the most important chronic liver disorders worldwide. Adipokines are polypeptide hormones that participate in the pathogenesis of non-alcoholic fatty liver disease. Adiponectin is an adipokine that stimulates fatty acid oxidation in muscle and plays a role in the development of insulin sensitivity. This study aimed to investigate the assoc...

The role of NAFLD in cardiometabolic disease: an update

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis-induced cirrhosis increased by 170% from 2004 t...

Evaluation of the effects of resveratrol on non-alcoholic fatty liver disease A systematic review study

Introduction: Non-alcoholic fatty liver disease (NAFLD) is a condition in which triglycerides accumulate in liver cells without a history of alcohol consumption. Evidence has shown that auxiliary treatments, including the use of antioxidant compounds, can be effective in improving nonalcoholic fatty liver. Resveratrol is an antioxidant compound that has been shown to be beneficial in some disea...

Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH

PETACH TIKVA, Israel, May 3, 2017 /PRNewswire/ -Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on a Phase II clinical trial to evaluate its liver drug candidate Namodenoson (CF102) in the treatment of non-alcoholic fatty liver disease...

Update on Current Standards of Care in the Diagnosis and Management of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): Diagnosis

Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease

non-alcoholic fatty liver disease (naflD) has emerged as a worldwide epidemic in the 21st century. the spectrum of its histopathology ranges from simple steatosis to steatohepatitis, with risk for progressive fibrosis that may lead to cirrhosis and hepatocellular carcinoma. this review is an update of the histopathology of naflD and its differential diagnosis, in particular alcoholic liver dise...